Renal involvement in rheumatoid arthritis
More details
Hide details
Submission date: 2014-01-28
Final revision date: 2014-05-13
Acceptance date: 2014-09-16
Online publication date: 2014-11-17
Publication date: 2014-10-31
Reumatologia 2014;52(5):311–318
Renal involvement is still a significant problem in rheumatoid arthritis (RA) patients. Reduced kidney function is detected in 5–50% of them and is more prevalent than in the general population. During the last decades the picture of renal disease has changed due to earlier and more aggressive therapy of arthritis. Nephrotoxic drugs are withdrawn or used very rarely. Because of successful reduction of the inflammatory process, amyloidosis has become rare, as have other severe complications of active disease such as vasculitis. Acute renal failure is now very infrequent, but chronic kidney disease (CKD) still makes an important contribution to morbidity and mortality. Recent studies are focused on the association between CKD and chronic cardiovascular disease (CVD). The relation appears comparable to the association observed in diabetes mellitus. In the article we summarize the results of studies on renal disease in RA, including histopathology, risk factors and markers of renal involvement.
Aggarval HK, Singh H, Jain D, et al. Histofunctional status of kidney in patients with rheumatoid arthritis. Dicle Med J 2011; 38: 375-381. .
Kaplan MJ. Cardiovascular complications of rheumatoid arthritis-assessment, prevention and treatment. Rheum Dis Clin North Am 2010; 36: 405-426. .
Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis 2013; 63: 206-213. .
Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008; 47: 350-354. .
Loza E, Jover JA, Rodriguez-Rodriguez L, Carmona L. Observed and expected frequency of comorbid chronic diseases in rheumatic patients. Ann Rheum Dis 2008; 67: 418-421. .
Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis 1987; 46: 658-663. .
Makino H, Yoshinaga Y, Yamasaki Y, et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol 2002; 12: 148-154. .
Helin H, Korpela M, Mustonen J, Pasternack A. Mild mesangial glomerulopathy: a frequent finding in rheumatoid arthritis patients with hematuria or proteinuria. Nephron 1986; 42: 224-230. .
Nakano M, Ueno M, Nishi S, et al. Determination of IgA ad IgM rheumatic factors in patients with rheumatoid arthritis with and without nephropathy. Ann Rheum Dis 1996; 55: 520-524. .
Korpela M, Mustonen J, Teppo AM, et al. Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol 1997; 36: 1189-1195. .
Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995; 38: 242-247. .
Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013; 11: 95. .
Koivuniemi R, Paimela L, Suomalainen R, et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15: 262-268. .
Kuroda T, Tanabe N, Sakatsume M, et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rhematol 2002; 21: 123-128. .
Wakhlu A, Krisnani N, Hissaria P, et al. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003; 30: 948-951. .
Wiland P, Wojtała R, Goodacre J. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheum 2004; 23: 193-198. .
Kuroda T, Tanabe N, Kobayashi D, et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis. Rheumatol Int 2012; 32: 3155-3162. .
Uda H, Yokota A, Kobayashi K, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 2006; 33: 1482-1487. .
Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis 2000; 59: 577-579. .
Gómez-Casanovas E, Sanmartí R, Solé M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44: 66-72. .
Genta M, Genta R, Gabay C. Systemic Rheumatoid vasculitis: a review. Semin Arthritis Rheum 2006; 36: 88-98. .
Anders HJ, Vielhauer V. Renal co-morbidity in patients with rheumatic diseases. Arthritis Res Ther 2011; 13: 222. .
Koseki Y, Terai C, Moriguchi M, et al. A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 327-331. .
Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process and damage. Ann Rhem Dis 2002; 61: 1055-1059. .
Turesson C, O’Fallon WM, Crowson CS, et al. Extra-articular manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-727. .
Karstila K, Korpela M, Sihvonen S, Mustonen J. Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of the population-based study. Clin Rheumatol 2007; 26: 2089-2095. .
Sihvonen S, Korpela M, Mustonen J, et al. Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron Clin Pract 2004; 96: c107-114. .
Daoussis D, Panoulas V, Toms T, et al. Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11: R116. .
Daoussis D, Panoulas VF, Antonopoulos I, et al. Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 517-521. .
Haroon M, Adeeb F, Devlin J, et al. A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis. Int J Rheum Dis 2011; 14: 255-260. .
van Sijl AM, van den Oever IA, Peters MJ, et al. Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRÉ study. Ann Rheum Dis 2012; 71: 341-344. .
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-S266. .
Anders HJ, Rihl M, Vielhauer V, Schattenkirchner M. Prediction of creatinine clearance from serum creatinine in patients with rheumatoid arthritis: comparison of six formulae and one nomogram. Clin Rheumatol 2002; 8: 130-133. .
Pathan E, Joshi VR. Rheumatoid arthritis and the kidney. J Assoc Physicians India 2004; 52: 488-494. .
Mangge H, Liebmann P, Tanil H, et al. Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta 2000; 300: 195-202. .
Karstila K, Harmoinen AP, Lehtimäki TJ, et al. Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance. Nephron Clin Pract 2008; 108: c284-c290. .
Niederstadt C, Happ T, Tatsis E, et al. Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 28-33. .
Iqbal M, Waqar M, Mehboobali N, et al. Urinary N-acetyl-D-glucosamidase in rheumatoid arthritis. Exp Mol Med 1998; 30: 95-101. .
Wiland P, Swierkot J, Szechiński J. N-acetyl-D-glucosamidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Br J Rheumatol 1997; 36: 59-63. .
Spasovski D, Gruev T, Marina N, et al. The diagnostic value of N-acetyl--D-glucosamidase and microalbumin concentration in rheumatoid arthritis. JMB 2007; 26: 300-308. .
Viergever P, Swaak A. Urine and serum beta-2-microglobulin in patients with rheumatoid arthritis: a study of 101 patients without signs of kidney disease. Clin Rheum 1989; 8: 368-374. .
Pedersen LM, Nordin H, Svensson B, Bliddal H. Microalbuminuria in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 189-192. .
Nordin H, Pedersen LM, Svensson BH, Bliddal H. Microalbuminuria in rheumatoid arthritis. Ugersk Laeger 1996; 158: 3141-3143 [Abstract]. .
Mpofu S, Kaushik VV, Grundy G, Moots RJ. Microalbuminuria: is it a predictor of ischaemic heart disease in rheumatoid arthritis? Rheumatology (Oxford) 2004; 43: 537-538. .
Bhatt G, Mathur D, Saxena G, et al. Micoralbuminuria in rheumatoid arthritis a correlation with disease activity. J Assoc Phys India 2002; 50: 82. .
Verma M, Shanker V, Singh H, et al. Microalbuminuria: a marker of severe disease activity in rheumatoid arthritis. Indian J Rheum 2013; 8: 112-116. .
Daoussis D, Panoulas VF, John H, et al. Microalbuminuria in rheumatoid arthritis in the post gold/penicillamine era: association with hypertension, but not therapy or inflammation. Clin Rheumatol 2011; 30: 477-484. .
Panoulas VF, Toms TE, Metsios GS, et al. Target organ damage in patients with rheumatoid arthritis: The role of blood pressure and heart rate. Atherosclerosis 2010; 209: 255-260. .
Pathan E, Gaitonde S, Rajadhyaksha S, et al. A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J Assoc Physicians India 2003; 51: 1045-1049. .
Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondylitis). Cochrane Database Syst Rev 2011; 11: CD008872. .
Seideman P, Müller-Suur R. Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 1993; 52: 613-615. .
Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2013. doi: 10.1136/annrheumdis-2012-203137. .
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509. .
Al-Hasani H, Roussou E. Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int 2011; 31: 1545-1547. .
Don BR, Kim K, Li J, et al. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 2010; 73: 431-438. .
Senel S, Kisacik B, Ugan Y, et al. The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 2011; 30: 1369-1372. .
Nakamura T, Higashi S, Tomoda K, et al. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2010; 29: 1395-1401. .
Keersmaekers T, Claes K, Kuypers DR, et al. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis 2009; 68: 759-761. .
Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNFα therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406. .
Chen TJ, Yang YF, Huang PH, et al. Permanent renal loss following tumor necrosis factor  antagonists for arthritis. Rheumatol Int 2010; 30: 1077-1079.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.